Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer

BACKGROUND: Unresectable gastric cancer is associated with poor outcomes, with few treatment options available after failure of cytotoxic chemotherapy. Clinical trials of targeted therapies have generally shown no survival benefit in gastric cancer, with the exceptions of the antibodies ramucirumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Huynh, Hung, Ong, Richard, Zopf, Dieter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4625870/
https://www.ncbi.nlm.nih.gov/pubmed/26514182
http://dx.doi.org/10.1186/s13046-015-0243-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4625870/
https://www.ncbi.nlm.nih.gov/pubmed/26514182
http://dx.doi.org/10.1186/s13046-015-0243-5

Ejemplares similares